

SUPPLEMENTARY MATERIALS

REAL-WORLD USE OF ABROCITINIB FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE UNITED STATES BASED ON ELECTRONIC HEALTH RECORDS AND ADMINISTRATIVE CLAIMS

Raj Chovatiya MD, PhD, MSCI^{a,b}; Amanda Mummert PhD^c; Stella Chang MPH^c; Mark Levenberg DO^d; Griffith Bell MPH PhD^e; Amie Scott MPH^f; Melissa Watkins MSc, PhD^f

^aRosalind Franklin University of Medicine and Science Chicago Medical School, North Chicago, IL, USA; ^bCenter for Medical Dermatology + Immunology Research, Chicago, IL, USA; ^cOMNY Health, Atlanta, GA, USA; ^dPfizer Inc., Collegeville, PA, USA; ^ePfizer Inc., Cambridge, MA, USA; ^fPfizer Inc., New York, NY, USA

Corresponding author:

Melissa Watkins, MSc, PhD

Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001-2192 USA

Email: melissa.watkins@pfizer.com

Contents	Page
Table S1. List of pre-index AD treatments by category of therapy	2
Table S2. Baseline patient demographics and pre-index clinical characteristics by age category, abrocitinib dose, and line of therapy at index	5
Table S3. Pre-index comorbidities by age category, abrocitinib dose, and line of therapy at index	7
Table S4. Pre-index exposure to AD treatments by age category, abrocitinib dose, and line of therapy at index	8
Table S5. Abrocitinib dose changes and persistence of treatment post index by age category, abrocitinib dose, and line of therapy at index	9
Fig S1. Study design	11
Fig S2. Patient attrition according to patient age	12
Fig S3. Severity of AD at index in patients with ClinRO/PRO data	13
Fig S4. Scatterplots of ClinROs and PROs over time in patients receiving abrocitinib as measured by (A) BSA, (B) itch NRS, and (C) IGA	14
Supplementary Appendix: Prior publications of abrocitinib linked claims and electronic health records in the United States	15

15 **Table S1. List of pre-index AD treatments by category of therapy**

Category of therapy	Specific pre-index AD treatments
Topical treatments	Phosphodiesterase 4 inhibitors
	Crisaborole
	Roflumilast
	Topical aryl hydrocarbon receptor agonist
	Tapinarof
	Topical calcineurin inhibitors
	Pimecrolimus
	Tacrolimus
	Topical corticosteroids
	Alclometasone (topical)
	Amcinonide (topical)
	Betamethasone (topical)
	Clobetasol (topical)
	Clocortolone pivalate (topical)
	Desonide (topical)
	Desoximetasone (topical)
	Dexamethasone (topical)
	Diflorasone (topical)
	Fluocinolone acetonide (topical)
	Fluocinonide (topical)
	Flurandrenolide (topical)
	Fluticasone propionate (topical)
	Halcinonide (topical)
	Halobetasol propionate (topical)

	Hydrocortisone (topical) Methylprednisolone (topical) Mometasone furoate (topical) Prednicarbate (topical) Triamcinolone (topical) Topical JAK inhibitors Ruxolitinib
Phototherapy	Phototherapy
Oral systemic corticosteroids	Betamethasone (oral) Budesonide (oral) Cortisone (oral) Deflazacort (oral) Dexamethasone (oral) Fludrocortisone (oral) Hydrocortisone (oral) Methylprednisolone (oral) Prednisolone (oral) Prednisone (oral) Triamcinolone (oral) Vamorolone (oral)
Parenteral systemic corticosteroids	Betamethasone (parenteral) Cortisone (parenteral) Dexamethasone (parenteral) Hydrocortisone (parenteral) Methylprednisolone (parenteral) Prednisolone (parenteral) Triamcinolone (parenteral)

Conventional systemic immunosuppressants	Azathioprine Cyclosporine Methotrexate Mycophenolate
Systemic biologic agents	Dupilumab Lebrikizumab Nemolizumab Tralokinumab
Oral JAK inhibitors	Abrocitinib Upadacitinib

16

17

18 **Table S2. Baseline patient demographics and pre-index clinical characteristics by age category, abrocitinib dose, and line of**
 19 **therapy at index**

	Total (N=401)	Age at index		Abrocitinib dose at index			Line of therapy			
		Adolescent (N=34)	Adult (N=367)	50 mg (N=14)	100 mg (N=328)	200 mg (N=59)	1st line (N=289)	2nd line (N=90)	3rd line (N=15)	4th line+ (N=7)
Age	N=401	N=34	N=367	N=14	N=328	N=59	N=289	N=90	N=15	N=7
Mean (SD), years	45.0 (20.6)	15.4 (1.5)	47.8 (19.4)	62.3 (22.5)	45.4 (20.6)	38.8 (17.5)	45.7 (21.0)	41.8 (19.6)	48.5 (16.9)	53.9 (23.0)
Median (Q1–Q3), years	45 (26–65)	16 (14–17)	48 (29–66)	69 (58–80)	45 (26–65)	38 (25–51)	45 (26–66)	42 (25–56)	50 (42–57)	57 (35–71)
≥65 years, n (%)	102 (25.4)	NA	102 (27.8)	9 (64.3)	88 (26.8)	5 (8.5)	82 (28.4)	14 (15.6)	3 (20.0)	3 (42.9)
Female sex, n (%)	N=401	N=34	N=367	N=14	N=328	N=59	N=289	N=90	N=15	N=7
	243 (60.6)	17 (50.0)	226 (61.6)	6 (42.9)	206 (62.8)	31 (52.5)	169 (58.5)	58 (64.4)	10 (66.7)	6 (85.7)
Race, n (%)	N=340	N=27	N=313	N=12	N=276	N=52	N=242	N=80	N=11	N=7
White	147 (43.2)	11 (40.7)	136 (43.5)	4 (33.3)	121 (43.8)	22 (42.3)	101 (41.7)	36 (45.0)	8 (72.7)	2 (28.6)
Black or African American	35 (10.3)	2 (7.4)	33 (10.5)	1 (8.3)	31 (11.2)	3 (5.8)	26 (10.7)	7 (8.8)	1 (9.1)	1 (14.3)
Asian	21 (6.2)	2 (7.4)	19 (6.1)	1 (8.3)	17 (6.2)	3 (5.8)	12 (5.0)	7 (8.8)	1 (9.1)	1 (14.3)
American Indian or Alaska Native	5 (1.5)	0	5 (1.6)	0	5 (1.8)	0	3 (1.2)	1 (1.3)	0	1 (14.3)
Native Hawaiian or other Pacific Islander	2 (0.6)	0	2 (0.6)	0	2 (0.7)	0	2 (0.8)	0	0	0
Other/unknown	130 (38.2)	12 (44.4)	118 (37.7)	6 (50.0)	100 (36.2)	24 (46.2)	98 (40.5)	29 (36.3)	1 (9.1)	2 (28.6)
Ethnicity, n (%)	N=340	N=27	N=313	N=12	N=276	N=52	N=242	N=80	N=11	N=7
Hispanic or Latinx	22 (6.5)	5 (18.5)	17 (5.4)	1 (8.3)	15 (5.4)	6 (11.5)	15 (6.2)	6 (7.5)	0	1 (14.3)
Not Hispanic or Latinx	155 (45.6)	12 (44.4)	143 (45.7)	6 (50.0)	131 (47.5)	18 (34.6)	109 (45.0)	35 (43.8)	8 (72.7)	3 (42.9)
Unknown	163 (47.9)	10 (37.0)	153 (48.9)	5 (41.7)	130 (47.1)	28 (53.9)	118 (48.8)	39 (48.8)	3 (27.3)	3 (42.9)

	Total (N=401)	Age at index		Abrocitinib dose at index			Line of therapy			
		Adolescent (N=34)	Adult (N=367)	50 mg (N=14)	100 mg (N=328)	200 mg (N=59)	1st line (N=289)	2nd line (N=90)	3rd line (N=15)	4th line+ (N=7)
Body mass index	N=96	N=6	N=90	N=4	N=78	N=14	N=58	N=28	N=7	N=3
Mean (SD), kg/m ²	28.6 (7.4)	30.0 (6.3)	28.6 (7.5)	25.3 (9.4)	28.4 (7.3)	30.9 (7.3)	29.7 (7.7)	28.5 (6.9)	22.9 (3.4)	21.8 (2.0)
Median (Q1–Q3), kg/m ²	28.2 (22.9–32.5)	31.0 (26.3–34.3)	28.0 (22.7–32.3)	25.4 (18.1–32.6)	27.0 (22.5–33.0)	30.9 (27.8–32.1)	30.3 (23.8–33.6)	27.4 (23.5–32.7)	22.4 (20.7–25.6)	21.4 (20.7–22.7)
≥30 kg/m ² , n (%)	41 (42.7)	4 (66.7)	37 (41.1)	2 (50.0)	31 (39.7)	8 (57.1)	30 (51.7)	11 (39.3)	0	0
Time since AD diagnosis	N=401	N=34	N=367	N=14	N=328	N=59	N=289	N=90	N=15	N=7
Mean (SD), years	4.2 (2.4)	5.2 (2.3)	4.2 (2.4)	3.5 (2.9)	4.2 (2.4)	4.9 (2.6)	4.1 (2.5)	4.5 (2.2)	5.6 (1.8)	4.0 (2.3)
Median (Q1–Q3), years	4.3 (2.2–6.2)	6.2 (2.7–7.0)	4.2 (2.1–6.1)	3.2 (1.1–6.0)	4.3 (2.2–6.1)	5.2 (2.6–7.2)	4.0 (2.0–6.2)	4.4 (2.7–6.2)	6.1 (4.5–6.6)	5.1 (2.5–5.5)
≥5 years, n (%)	175 (43.6)	23 (67.7)	152 (41.4)	4 (28.6)	141 (43.0)	30 (50.9)	119 (41.2)	42 (46.7)	10 (66.7)	4 (57.1)
Severity of AD at index, n (%)^a										
Itch NRS	N=40	N=2	N=38	N=0	N=32	N=8	N=32	N=6	N=1	N=1
Moderate	9 (22.5)	1 (50.0)	8 (21.1)	-	8 (25.0)	1 (12.5)	7 (21.9)	1 (16.7)	0	1 (100.0)
Severe	23 (57.5)	1 (50.0)	22 (57.9)	-	16 (50.0)	7 (87.5)	18 (56.3)	5 (83.3)	0	0
IGA	N=42	N=4	N=38	N=0	N=34	N=8	N=33	N=6	N=2	N=1
Moderate	18 (42.9)	1 (25.0)	17 (44.7)	-	15 (44.1)	3 (37.5)	15 (45.5)	2 (33.3)	0	1 (100.0)
Severe	15 (35.7)	2 (50.0)	13 (34.2)	-	11 (32.4)	4 (50.0)	11 (33.3)	4 (66.7)	0	0
BSA	N=44	N=4	N=40	N=0	N=35	N=9	N=34	N=8	N=1	N=1
Moderate	21 (47.7)	3 (75.0)	18 (45.0)	-	17 (48.6)	4 (44.4)	17 (50.0)	2 (25.0)	1 (100.0)	1 (100.0)
Severe	17 (38.6)	0	17 (42.5)	-	12 (34.3)	5 (55.6)	12 (35.3)	5 (62.5)	0	0

^aModerate AD was defined as as itch NRS 4–<7, IGA 3, and BSA 10–<30%; severe AD was defined as as itch NRS ≥7, IGA 4, and BSA ≥30%.

AD, atopic dermatitis; BSA, body surface area; IGA, Investigator Global Assessment; NRS, numerical rating scale; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.

22 **Table S3. Pre-index comorbidities by age category, abrocitinib dose, and line of therapy at index**

n (%) ^{*,†}	Total (N=401)	Age at index		Abrocitinib dose at index			Line of therapy			
		Adolescent (N=34)	Adult (N=367)	50 mg (N=14)	100 mg (N=328)	200 mg (N=59)	1st line (N=289)	2nd line (N=90)	3rd line (N=15)	4th line+ (N=7)
Overweight/obese	184 (45.9)	17 (50.0)	167 (45.5)	11 (78.6)	140 (42.7)	33 (55.9)	133 (46.0)	42 (46.7)	5 (33.3)	4 (57.1)
Anxiety	169 (42.1)	9 (26.5)	160 (43.6)	5 (35.7)	136 (41.5)	28 (47.5)	115 (39.8)	43 (47.8)	5 (33.3)	6 (85.7)
Allergic rhinitis	159 (39.7)	17 (50.0)	142 (38.7)	4 (28.6)	133 (40.6)	22 (37.3)	107 (37.0)	46 (51.1)	5 (33.3)	1 (14.3)
Contact dermatitis	152 (37.9)	8 (23.5)	144 (39.2)	4 (28.6)	118 (36.0)	30 (50.9)	109 (37.7)	30 (33.3)	9 (60.0)	4 (57.1)
Dyslipidemia	150 (37.4)	4 (11.8)	146 (39.8)	9 (64.3)	126 (38.4)	15 (25.4)	110 (38.1)	27 (30.0)	7 (46.7)	6 (85.7)
Hypertension	134 (33.4)	3 (8.8)	131 (35.7)	10 (71.4)	105 (32.0)	19 (32.2)	93 (32.2)	33 (36.7)	6 (40.0)	2 (28.6)
Depression	137 (34.2)	8 (23.5)	129 (35.2)	6 (42.9)	105 (32.0)	26 (44.1)	94 (32.5)	36 (40.0)	3 (20.0)	4 (57.1)
Asthma	140 (34.9)	14 (41.2)	126 (34.3)	6 (42.9)	102 (31.1)	32 (54.2)	98 (33.9)	35 (38.9)	7 (46.7)	0
Conjunctivitis/keratitis	101 (25.2)	9 (26.5)	92 (25.1)	7 (50.0)	73 (22.3)	21 (35.6)	71 (24.6)	25 (27.8)	5 (33.3)	0
Hand eczema	101 (25.2)	2 (5.9)	99 (27.0)	4 (28.6)	83 (25.3)	14 (23.7)	73 (25.3)	19 (21.1)	6 (40.0)	3 (42.9)
Smoking	102 (25.4)	1 (2.9)	101 (27.5)	3 (21.4)	87 (26.5)	12 (20.3)	67 (23.2)	28 (31.1)	6 (40.0)	1 (14.3)
Cataract	81 (20.2)	0	81 (22.1)	8 (57.1)	64 (19.5)	9 (15.3)	65 (22.5)	12 (13.3)	1 (6.7)	3 (42.9)
Cellulitis infection	77 (19.2)	7 (20.6)	70 (19.1)	4 (28.6)	62 (18.9)	11 (18.6)	52 (18.0)	22 (24.4)	2 (13.3)	1 (14.3)
Food allergy	65 (16.2)	12 (35.3)	53 (14.4)	1 (7.1)	53 (16.2)	11 (18.6)	38 (13.2)	23 (25.6)	4 (26.7)	0
Type 2 diabetes	59 (14.7)	3 (8.8)	56 (15.3)	4 (28.6)	44 (13.4)	11 (18.6)	40 (13.8)	13 (14.4)	5 (33.3)	1 (14.3)
DVT/VTE	11 (2.7)	0	11 (3.0)	2 (14.3)	9 (2.7)	0	7 (2.4)	2 (2.2)	1 (6.7)	1 (14.3)

23 *Comorbidities were recorded in the EHR and linked claim.

24 †The most common comorbidities (i.e., those reported in ≥20% of patients in any group) and other key comorbidities are shown.

25 AD, atopic dermatitis; DVT, deep vein thrombosis; VTE, venous thromboembolism.

26 **Table S4. Pre-index exposure to AD treatments by age category, abrocitinib dose, and line of therapy at index**

n (%)	Total (N=401)	Age at index		Abrocitinib dose at index			Line of therapy			
		Adolescent (N=34)	Adult (N=367)	50 mg (N=14)	100 mg (N=328)	200 mg (N=59)	1st line (N=289)	2nd line (N=90)	3rd line (N=15)	4th line+ (N=7)
Topical treatments*	291 (72.6)	24 (70.6)	267 (72.8)	12 (85.7)	238 (72.6)	41 (69.5)	209 (72.3)	65 (72.2)	11 (73.3)	6 (85.7)
Phototherapy	27 (6.7)	1 (2.9)	26 (7.1)	1 (7.1)	23 (7.0)	3 (5.1)	22 (7.6)	2 (2.2)	3 (20.0)	0
Oral systemic corticosteroids	180 (44.9)	10 (29.4)	170 (46.3)	9 (64.3)	145 (44.2)	26 (44.1)	131 (45.3)	38 (42.2)	8 (53.3)	3 (42.9)
Parenteral systemic corticosteroids	175 (43.6)	4 (11.8)	171 (46.6)	7 (50.0)	142 (43.3)	26 (44.1)	123 (42.6)	39 (43.3)	11 (73.3)	2 (28.6)
Conventional systemic immunosuppressants	40 (10.0)	1 (2.9)	39 (10.6)	0	32 (9.8)	8 (13.6)	18 (6.2)	17 (18.9)	5 (33.3)	0
Systemic biologic agents [†]	91 (22.7)	11 (32.4)	80 (21.8)	1 (7.1)	80 (24.4)	10 (17.0)	0	69 (76.7)	15 (100.0)	7 (100.0)
Oral JAK inhibitors [‡]	40 (10.0)	2 (5.9)	38 (10.4)	1 (7.1)	30 (9.2)	9 (15.3)	0	22 (24.4)	14 (93.3)	4 (57.1)

27 Treatments received are based on paid claims in the pre-index period.

28 *Includes topical corticosteroids, topical calcineurin inhibitors, topical AHR agonists, topical JAK inhibitors, and topical PDE4 inhibitors.

29 [†]Includes dupilumab, tralokinumab, and lebrikizumab.30 [‡]Upadacitinib.

31 AD, atopic dermatitis; AHR, aryl hydrocarbon receptor; EHR, electronic health record; JAK, Janus kinase; PDE4, phosphodiesterase 4.


32 **Table S5. Abrocitinib dose changes and persistence of treatment post index by age category, abrocitinib dose, and line of therapy**
 33 **at index**

	Total (N=401)	Age at index		Abrocitinib dose at index			Line of therapy			
		Adolescent (N=34)	Adult (N=367)	50 mg (N=14)	100 mg (N=328)	200 mg (N=59)	1st line (N=289)	2nd line (N=90)	3rd line (N=15)	4th line+ (N=7)
Abrocitinib dose change from index, n (%)										
Within 4-months post index	N=253	N=23	N=230	N=8	N=205	N=40	N=178	N=60	N=9	N=6
Increase only	16 (6.3)	1 (4.4)	15 (6.5)	2 (25.0)	14 (6.8)	0	9 (5.1)	5 (8.3)	2 (22.2)	0
Decrease only	6 (2.4)	0	6 (2.6)	0	4 (2.0)	2 (5.0)	4 (2.3)	1 (1.7)	0	1 (16.7)
No change	231 (91.3)	22 (95.7)	209 (90.9)	6 (75.0)	187 (91.2)	38 (95.0)	165 (92.7)	54 (90.0)	7 (77.8)	5 (83.3)
Within 6-months post index	N=255	N=24	N=231	N=9	N=206	N=40	N=180	N=60	N=9	N=6
Increase only	16 (6.3)	1 (4.2)	15 (6.5)	2 (22.2)	14 (6.8)	0	9 (5.0)	5 (8.3)	2 (22.2)	0
Decrease only	6 (2.4)	0	6 (2.6)	0	4 (1.9)	2 (5.0)	4 (2.2)	1 (1.7)	0	1 (16.7)
No change	233 (91.4)	23 (95.8)	210 (90.9)	7 (77.8)	188 (91.3)	38 (95.0)	167 (92.8)	54 (90.0)	7 (77.8)	5 (83.3)
Within 12-months post index	N=260	N=25	N=235	N=9	N=211	N=40	N=184	N=61	N=9	N=6
Increase only	18 (6.9)	1 (4.0)	17 (7.2)	2 (22.2)	16 (7.6)	0	9 (4.9)	6 (9.8)	3 (33.3)	0
Decrease only	6 (2.3)	0	6 (2.6)	0	4 (1.9)	2 (5.0)	4 (2.2)	1 (1.6)	0	1 (16.7)
No change	236 (90.8)	24 (96.0)	212 (90.2)	7 (77.8)	191 (90.5)	38 (95.0)	171 (92.9)	54 (88.5)	6 (66.7)	5 (83.3)
Time (days) to first dose change										
	N=28	N=1	N=27	N=2	N=24	N=2	N=17	N=7	N=3	N=1
Mean (SD)	145.9 (194.1)	105 (-)	147.4 (197.6)	63.0 (-)	160.1 (206.4)	58.5 (51.6)	175.4 (236.6)	100.9 (83.2)	129.3 (125.3)	10 (-)
Median (Q1–Q3)	63.0 (40.8–118.8)	105.0 (-)	63.0 (39.5– 119.0)	63.0 (63.0–63.0)	61.5 (40.8–155.8)	58.5 (40.3–76.8)	63.0 (42.0–118.0)	105.0 (41.0–118.5)	59.0 (57.0–166.5)	10 (-)

	Total (N=401)	Age at index		Abrocitinib dose at index			Line of therapy			
		Adolescent (N=34)	Adult (N=367)	50 mg (N=14)	100 mg (N=328)	200 mg (N=59)	1st line (N=289)	2nd line (N=90)	3rd line (N=15)	4th line+ (N=7)
Abrocitinib early persistence, n (%)										
Fill within 60 days of index	N=378 230 (60.8)	N=32 22 (68.8)	N=346 208 (60.1)	N=14 6 (42.9)	N=314 189 (60.2)	N=50 35 (70.0)	N=275 164 (59.6)	N=81 51 (63.0)	N=15 9 (60.0)	N=7 6 (85.7)
Time (days) between index date and second fill of abrocitinib										
Mean (SD)	N=378 21.1 (14.0)	N=32 20.7 (12.1)	N=346 21.1 (14.2)	N=14 24 (7.0)	N=314 20.3 (14.2)	N=50 25.0 (13.0)	N=275 21.0 (13.7)	N=81 20.7 (14.0)	N=15 23.1 (20.7)	N=7 22.7 (15.1)
Median (Q1–Q3)	24.0 (7.3–29.0)	25.0 (6.8–28.0)	24.0 (7.8–30.0)	26.0 (23.0–27.5)	23.0 (6.0–28.0)	27.0 (20.5–31.0)	23.5 (8.0–30.3)	26.0 (3.5–28.0)	24.0 (4.0–36.0)	25.0 (13.8–28.0)

34 Q1, quartile 1; Q3, quartile 3; QD, once daily; SD, standard deviation.

35 **Fig S1. Study design**



36

37 *Baseline period (including index): ≥180 days of EHR and/or linked claims data available prior to
38 index.


39 †Index: date of first paid claim for abrocitinib (earliest date January 14, 2022 for adults and February
40 9, 2023 for adolescents).

41 ‡Based on International Classification of Diseases 10th Revision, Clinical Modification (ICD-10-CM)
42 diagnosis code for AD, defined as L20.0, L20.81, L20.82, L20.83, L20.84, L20.89, L20.9, L30.8, or
43 L30.9.

44 §Follow-up period: until the end of linked EHR claims data, initiation of an alternative advanced
45 systemic treatment, or loss to follow-up.

46 AD, atopic dermatitis; EHR, electronic health record.


Fig S2. Patient attrition according to patient age



*Diagnosis codes included: ICD-10-CM L20.0, L20.81, L20.82, L20.83, L20.84, L20.89, L20.9, L30.8, or L30.9.

AD, atopic dermatitis; ClinRO, clinician-reported outcome; ICD-10-CM, International Classification of Diseases 10th Revision, Clinical Modification; PRO, patient-reported outcome.


Fig S3. Severity of AD at index in patients with ClinRO/PRO data



Severity measurement was captured on or within 42 days of the preceding index date. Itch NRS score categories were: 0, no itch; 1–3, mild itch; 4–6, moderate itch; and ≥7, severe itch. IGA score categories were: 0, clear; 1, almost clear; 2, mild; 3, moderate; and 4, severe. Total percentage may not sum to exactly 100% due to rounding of category values.

AD, atopic dermatitis; BSA, body surface area; ClinRO, clinician-reported outcome; IGA, Investigator Global Assessment; NRS, numeric rating scale; PRO, patient-reported outcome.

64 **Fig S4. Scatterplots of ClinROs and PROs over time in patients receiving abrocitinib as measured by (A) BSA, (B) itch NRS, and**
 65 **(C) IGA**



66

67 AD, atopic dermatitis; BSA, body surface area; ClinRO, clinician-reported outcome; IGA, Investigator Global Assessment; NRS, numeric
 68 rating scale; PRO, patient-reported outcome

69 **Supplementary Appendix: Prior publications of abrocitinib linked claims and electronic**
70 **health records in the United States**

71 **Database:** PubMed

72 **Date searches conducted:** March 4, 2026

73 **Date range of searches:** Any date

Search Terms	Number of results
(abrocitinib[Title/Abstract])	515
(abrocitinib[Title/Abstract]) AND (United States [Title/Abstract])	12
(abrocitinib[Title/Abstract]) AND (United States[Title/Abstract]) AND (real world[Title/Abstract])	1
(abrocitinib[Title/Abstract]) AND (United States[Title/Abstract]) AND (claims[Title/Abstract])	0
(abrocitinib[Title/Abstract]) AND (United States[Title/Abstract]) AND (electronic health records[Title/Abstract])	0
(abrocitinib[Title/Abstract]) AND (United States[Title/Abstract]) AND (electronic health records[Title/Abstract]) AND (claims[Title/Abstract])	0

74